Skip to main content

Advertisement

Table 3 Transcript levels of prognosis gene markers in B cells of CLL patients before treatment with fludarabine.

From: Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia

  CLL-11 CLL-2 CLL-3R2 CLL-4 CLL-5 CLL-6R2
ATM 1.00 3 1.10 0.42 3 1.91 0.52 3 2.32
BLM 1.00 0.54 1.32 0.79 0.92 2.06
CDK2AP1 1.00 0.52 2.59 0.33 0.70 1.75
DCLRE1A 1.00 1.26 2.84 0.12 1.27 3.11
MYC 1.00 1.36 20.33 4 0.95 1.42 34.39 4
PCNA 1.00 0.43 2.85 0.59 0.61 1.49
SULF2 1.00 0.4 72.6 4.8 2.5 157.4
TP53 1.00 0.94 0.04 5 1.12 0.70 0.62 5
UMPS 1.00 0.73 1.33 0.71 0.73 1.53
XPC 1.00 0.98 0.23 1.43 1.56 0.43
  1. 1 Ct values from this patient were used for normalization to compare expression levels between patients with the ΔΔCt calculation method.
  2. 2 Patient number followed by "R" indicates the refractoriness character to fludarabine.
  3. 3 A mono-allelic deletion on 11q22 was observed.
  4. 4 A gain on 8q was observed.
  5. 5 A mono-allelic deletion on 17p13 was observed.